Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Earl L. Goehring"'
Autor:
Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, George M. Martin, Nicole N. Rawnsley, Earl L. Goehring, Abby A. Jacobson
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1349-1357 (2024)
Abstract Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond o
Externí odkaz:
https://doaj.org/article/4d96df29b9fb43bc9db5f5236b669fdf
Autor:
Nicholas Sicignano, Sheila R. Weiss, Earl L. Goehring, Sally Tamayo, Arlene Tave, Chuntao Wu, Juhaeri Juhaeri, Vibha C. A. Desai, Judith K. Jones, Rhonda L. Bohn
Publikováno v:
Pharmacoepidemiology and Drug Safety
Purpose To compare risks of interstitial lung disease (ILD) between patients treated with dronedarone versus other antiarrhythmics. Methods Parallel retrospective cohort studies were conducted in the United States Department of Defense Military Healt
Autor:
Ret. Capt Sally G. Tamayo, Rhonda L. Bohn, Judith K. Jones, John Pezzullo, Arlene Tave, Sylvie Bozzi, Earl L. Goehring, Nicholas Sicignano, Gerald V. Naccarelli
Publikováno v:
The American journal of cardiology. 135
The antiarrhythmic drug dronedarone was designed to reduce the extra-cardiac adverse effects associated with amiodarone use in treatment of patients with atrial fibrillation / atrial flutter (AF/AFL). This epidemiological study used a retrospective c
Autor:
Bao-Anh Nguyen-Khoa, Judith K. Jones, Sigal Melamed-Gal, Sigal Kaplan, Helena Knebel, Earl L. Goehring
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:1182-1190
Purpose This study examined the potential risk of cardiovascular (CV) events associated with modafinil and the consistency of the risk estimates across databases. Methods A retrospective, inception cohort design of patients who initiated treatment wi
Publikováno v:
Drugs-Real World Outcomes
Purpose Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid-related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with
Autor:
Kimberly A. Alexander, Earl L. Goehring, Pavel Napalkov, Wei Dong, Judith K. Jones, Bao-Anh Nguyen-Khoa
Publikováno v:
Seminars in Arthritis and Rheumatism. 42:119-126
Objectives To describe rates of first significant infection of rheumatoid arthritis patients who switch between anti-tumor necrosis factor (aTNF) drugs. Methods Subjects with rheumatoid arthritis who received only aTNF drugs were observed in an insur
Autor:
Jay Levin, Peter Winters, Judith K. Jones, Earl L. Goehring, D. Eisenberg, Peter Wahl, Rhonda L. Bohn, Gregory W. Daniel
Publikováno v:
Pharmacoepidemiology and Drug Safety. 21:760-764
Purpose To validate the administrative claims identification of a diagnosis of Stevens–Johnson syndrome (SJS) using medical records as the “gold standard” in a large, commercially insured US population. Methods Patients with >1 medical claim wi
Autor:
Roger R. Dmochowski, Earl L. Goehring, Bao-Anh Nguyen-Khoa, Stephen P. Motsko, Cornelia Haag-Molkenteller, Judith K. Jones, Aubrey Manack
Publikováno v:
Neurourology and Urodynamics. 30:395-401
Aims To characterize the patient profile, medication utilization, and healthcare encounters of patients with neurogenic bladder dysfunction related to incontinence. Methods Medical and pharmacy claims were retrospectively analyzed from April 1, 2002
Publikováno v:
Pharmacoepidemiology and Drug Safety. 19:1031-1040
Objective To determine the prevalence of pediatric dyslipidemia in a large US medical insurance claims database and to compare the resulting estimate to the prevalence from the National Health and Nutrition Examination Survey (NHANES). Patients and M
Publikováno v:
Pharmacoepidemiology and Drug Safety. 19:90-98
Purpose To examine the rate of lipid testing among children from a large US medical insurance claims database, describe the characteristics of pediatric dyslipidemia, and assess the sensitivity of the International Classification of Disease, Ninth Re